eye drops delay, will prevent, myopia

Published Date: 16 Feb 2023

Researchers have found that dilating eye drops that children use daily can delay the onset of myopia.

Read Full News

Latest News

What Caused the Pigmented Spot on Teen Boy's Eye?

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

The HCPFive: Top News for Healthcare Providers from the Week of 01/25 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Latest News

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

News All Time

Consider This Before Cataract Surgery; Grant Rule: What's Next? CDC Nominee Grilled

MedPage Today reporters offer further insights into recently covered topics

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Similar results in patients who had port delivery system for 4 years or switched after 64 weeks

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 years

Drugs for Dry AMD Linked to Thickening of Retinal Nerve

More questions than answers, including whether the thickening is neuroprotective or pathologic

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

Branded Bevacizumab Approved for Wet AMD

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor

Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

Findings add to existing evidence linking the drug class to ophthalmic conditions

Medicare's Paying Less for Cataract Surgery. Ophthalmologists Are Turning to Lasers.

— Doctors typically charge $1,000 to $3,000 per eye for use of the laser

Medicare Is Paying Less for Cataract Surgery

Medicare pays doctors about $520 for a standard cataract procedure, down about 20% in the past decade.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

Massage Matches Clinic Probing for Infant Tear Duct Blockage

Gently massaging the tear sacs of infants with blocked tear ducts may be as effective as clinic-based probing for clearing tearing and discharge, a noninferiority trial finds.

Can Dexamethasone Drops Prevent Retinal Disease in Preemies?

Dexamethasone eye drops administered in premature infants with early-stage retinal disease appear to reduce the odds of progression to treatment-requiring disease.

Urinary Drug Tadalafil Linked to Glaucoma Risk

Men taking tadalafil for lower urinary tract symptoms face a 22% higher risk of developing glaucoma than those who do not take the drug, a new study finds.

Study Links Uveitis to Higher Risk for Psychiatric Illness

Noninfectious uveitis is linked to higher rates of psychiatric comorbidities, with Black patients most affected, a new study finds.

Recommended News For You

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

De-escalation Misses the Mark in Inflammatory Breast Cancer

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma

Study Questions How Prostate Cancer Focal Therapy Is Being Used

FDA Approves First Menin Inhibitor for Acute Leukemia

Recently released national data on drug use and abuse among Americans.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

Recommended Articles For You

Precision Oncology: Tailoring Cancer Treatment for the Individual 

Preserving Social Identity During Cancer Survivorship 

Everything You Need To Know About Splenic Infarction – Symptoms, Treatments, And Prevention 

The Future of Hemophilia Treatment: Long-Acting Therapies and Gene Editing 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

2.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

3.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

4.

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

5.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

1.

Bispecific Immune Activators in Cancer: Mechanisms, Evidence, and Clinical Implications

2.

Contemporary Insights in Oncology in the Digital Era

3.

Clinical Guidelines for Monitoring Bone Marrow Functional Reserve

4.

Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology

5.

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

3.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

4.

Early warning sings of camcer that need medical attention

5.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot